MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on November 1, 2007; DOI: 10.1124/mol.107.040725

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.040725v1
73/2/478    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robert, R.
Right arrow Articles by Hanrahan, J. W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robert, R.
Right arrow Articles by Hanrahan, J. W


Received for publication August 9, 2007.
Revised October 17, 2007.
Accepted for publication November 1, 2007.

Structural analogue of sildenafil identified as a novel corrector of the F508del-CFTR trafficking defect

Renaud Robert 1*, Graeme W Carlile 1, Catalin Pavel 1, Na Liu 1, Suzana M Anjos 1, Jie Liao 1, Yishan Luo 1, Donglei Zhang 1, David Y Thomas 1, John W Hanrahan 1

1 McGill University

* Address correspondence to: E-mail: renaud.robert{at}mcgill.ca

Abstract

The F508del mutation impairs trafficking of the cystic fibrosis transmembrane conductance regulator (CFTR) to the plasma membrane and results in a partially functional chloride channel that is retained in the endoplasmic reticulum and degraded. We recently used a novel High Throughput Screening (HTS) assay to identify small molecule correctors of F508del CFTR trafficking and found several classes of hits in a screen of 2000 compounds (Carlile et al., 2007). In the present study we have extended the screen to 42,000 compounds and confirmed sildenafil as a corrector using this assay. We evaluated structural analogues of sildenafil and found that one such molecule called KM11060 (7-chloro-4-{4-[(4-chlorophenyl) sulfonyl] piperazino}quinoline) was surprisingly potent. It partially restored F508del trafficking and increased maturation significantly when baby hamster kidney (BHK) cells were treated with 10 nM for 24 h or 10 µM for 2 h. Partial correction was confirmed by the appearance of mature CFTR in Western blots and by using halide flux, patch-clamp and short-circuit current measurements in unpolarized BHK cells, monolayers of human airway epithelial cells (CFBE41o-), and intestines isolated from F508del-CFTR mice ( Cftr tm1Eur) treated ex-vivo. Small molecule correctors such as KM11060 may serve as useful pharmacologic tools in studies of the F508del-CFTR processing defect and in the development of CF therapeutics.


Key words: cAMP, cGMP, Phosphodiesterases, Ion transporters (SERCA, Na/K ATPase, CFTR), Func. analysis receptor/ion channel mutants, Fluorescence techniques, Regulation - post-transcriptional


This article has been cited by other articles:


Home page
 Am. J. Respir. Cell Mol. Bio.Home page
J. F. Collawn, Z. Bebok, and S. Matalon
Search and Rescue: Finding Ways to Correct {Delta}F508 CFTR
Am. J. Respir. Cell Mol. Biol., April 1, 2009; 40(4): 385 - 387.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
A. M. Trzcinska-Daneluti, D. Ly, L. Huynh, C. Jiang, C. Fladd, and D. Rotin
High-content Functional Screen to Identify Proteins that Correct F508del-CFTR Function
Mol. Cell. Proteomics, April 1, 2009; 8(4): 780 - 790.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. Ratjen
Update in Cystic Fibrosis 2008
Am. J. Respir. Crit. Care Med., March 15, 2009; 179(6): 445 - 448.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics